60 Degrees Pharmaceuticals (SXTP) announced that the first patient to have completed the regimen in the Company’s trial of relapsing babesiosis in immunosuppressed patients has tested negative for babesiosis. The trial is an expanded access study of ARAKODA in combination with conventional treatments for relapsing babesiosis.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SXTP:
- 60 Degrees Pharmaceuticals Holds Annual Stockholders Meeting
- 60 Degrees Pharmaceuticals unveils name of chronic babesiosis trial
- 60 Degrees Pharmaceuticals Highlights ARAKODA Growth Potential
- 60 Degrees Pharmaceuticals Enters New Sales Agreement
- 60 Degrees selects Icahn School of Medicine as central site for Phase II study